|
시장보고서
상품코드
2126601
근위축성 측삭 경화증(ALS) 시장 : 약제 종류별, 투여 경로별, 제형별, 유통 채널별, 지역별Amyotrophic Lateral Sclerosis (ALS) Market, By Drug Type, By Route of Administration, By Dosage Form, By Distribution Channel, By Geography |
||||||
근위축성 측삭 경화증(ALS) 시장은 2026년에 18억 1,800만 달러 규모에 달할 것으로 추정되며, 2033년까지 39억 8,610만 달러에 달할 것으로 예상됩니다. 2026년부터 2033년까지 CAGR 11.9%로 성장할 것으로 전망됩니다.
| 보고서 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준 연도: | 2025년 | 2026년 시장 규모: | 18억 1,800만 달러 |
| 과거 데이터 기간: | 2020-2024년 | 예측 기간: | 2026-2033년 |
| 2026년부터 2033년까지 예측 기간의 CAGR: | 11.90% | 2033년 시장 규모 예측: | 39억 8,610만 달러 |
근위축성 측삭 경화증(ALS)은 루게릭병으로도 알려져 있으며, 의지근의 움직임을 제어하는 상운동뉴런 및 하운동뉴런의 변성과 사멸을 특징으로 하는 진행성 치명적 신경퇴행성 질환입니다. ALS 환자는 근력 저하, 경직, 근육 경련, 발화·연하·호흡 곤란을 보이며, 결국 마비나 호흡 부전에 이르게 됩니다. ALS는 남성에게서 더 많이 나타나며, 주로 40-70세 연령대에서 발병합니다. 사례의 5-10%는 가족성이며, 나머지는 산발성입니다.
세계 근위축성 측삭 경화증(ALS) 시장에는 치료제, 진단제, 보조 기술, 그리고 질병의 진행을 늦추고 증상을 완화하기 위해 개발 중인 새로운 치료법이 포함됩니다. 이 시장은 질병에 대한 인식 제고, 연구 자금 증가, 의약품 개발의 진전으로 인해 탄력을 받고 있으며, 이러한 요인들이 혁신을 촉진하여 제약 회사, 생명공학 기업 및 의료 관련 이해당사자들의 관심을 끌고 있습니다.
시장 역학
세계 근위축성 측삭 경화증(ALS) 시장은 환자 수 증가, 질병에 대한 인식 제고, 그리고 진단 및 치료의 확대에 힘입어 성장하고 있습니다. 릴졸(Riluzole) 및 에다라본(Edaravone)과 같은 치료법의 이용 가능성, 그리고 SOD1 관련 ALS에 대한 토페르센(Tofersen)과 같은 표적 치료법의 등장은 ALS 연구에 대한 투자를 촉진하고 있습니다.
그러나 근위축성 측삭 경화증(ALS) 시장의 성장은 치료비 급등, 개발도상국의 보험 환급 제한, 복잡한 질병의 생물학적 메커니즘, 그리고 임상시험의 높은 실패율과 같은 요인에 의해 제약을 받고 있습니다. 그럼에도 불구하고, SOD1, C9orf72, TARDBP, FUS 등 ALS 관련 돌연변이에 대한 유전학 연구의 진전이 정밀 의학 개발을 뒷받침하고 있으며, 생명공학 기업과 학술 기관 간의 협력 및 규제 당국의 신속한 승인 절차를 통해 유망한 치료법의 개발이 가속화되고 있습니다.
본 조사의 주요 특징
- 본 조사에서는 다양한 부문의 잠재적 수익 기회를 밝히고, 이 시장의 매력적인 투자 제안 매트릭스에 대해 해설하고 있습니다.
- 또한, 본 조사에서는 시장 촉진요인, 시장 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 그리고 주요 기업이 채택하고 있는 경쟁 전략에 관한 중요한 인사이트도 제공합니다.
- 본 조사에서는 다음 매개변수(기업 개요, 제품 포트폴리오, 주요 하이라이트, 재무 실적 및 전략)를 바탕으로 전 세계 근위축성 측삭 경화증(ALS) 시장의 주요 기업을 분석하고 있습니다.
- 본 보고서에서 얻을 수 있는 인사이트를 통해 기업의 마케팅 담당자 및 경영진은 향후 제품 출시, 제품 업그레이드, 시장 확대 및 마케팅 전략에 대해 충분한 정보를 바탕으로 의사결정을 내릴 수 있게 됩니다.
- 본 ‘세계 근위축성 측삭 경화증(ALS) 시장 보고서’는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입 기업, 금융 애널리스트 등 이 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자 여러분은 전 세계 근위축성 측삭 경화증(ALS) 시장 분석에 활용되는 다양한 전략 매트릭스를 통해 원활한 의사결정을 내릴 수 있을 것입니다.
목차
제1장 조사 목적과 가정
제2장 시장 전망
제3장 시장 역학·규제·동향 분석
제4장 세계의 근위축성 측삭 경화증(ALS) 시장 : 약물 유형별, 2021-2033년
제5장 세계의 근위축성 측삭 경화증(ALS) 시장 : 투여 경로별, 2021-2033년
제6장 세계의 근위축성 측삭 경화증(ALS) 시장 : 제형별, 2021-2033년
제7장 세계의 근위축성 측삭 경화증(ALS) 시장 : 유통 채널별, 2021-2033년
제8장 세계의 근위축성 측삭 경화증(ALS) 시장 : 지역별, 2021-2033년
제9장 경쟁 구도
제10장 애널리스트의 제안
제11장 참고문헌 및 조사 방법
KSM 26.09.09Amyotrophic Lateral Sclerosis (ALS) Market is estimated to be valued at USD 1,818.0 Mn in 2026 and is expected to reach USD 3,986.1 Mn by 2033, growing at a compound annual growth rate (CAGR) of 11.9% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 1,818.0 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 11.90% | 2033 Value Projection: | USD 3,986.1 Mn |
Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, is a progressive and fatal neurodegenerative disease characterized by degeneration and death of the upper and lower motor neurons that control voluntary muscle movements. ALS patients develop muscle weakness, stiffness, twitching and difficulty with talking, swallowing and breathing, eventually resulting in paralysis and respiratory failure. ALS is more common in males and affects mainly the age group of 40-70 years with 5-10% of cases being familial and the rest sporadic.
The global amyotrophic lateral sclerosis (ALS) market includes therapeutics, diagnostics, assistive technologies, and new pipeline therapies that seek to slow the disease progression and alleviate its symptoms. The market is gaining traction because of increased disease awareness, increased research funding, and advancements in drug development that are driving innovation and generating interest from pharmaceutical companies, biotechnology companies, and healthcare stakeholders.
Market Dynamics
The global amyotrophic lateral sclerosis (ALS) market is driven by increasing patient population, rising disease awareness, and increasing diagnosis and treatment. The availability of therapies like riluzole and edaravone, and the emergence of targeted therapies like tofersen for SOD1 associated ALS, are encouraging investments in ALS research.
However, the growth of amyotrophic lateral sclerosis (ALS) market is limited by factors such as high costs of treatment, limited reimbursement in developing economies, complex disease biology and high clinical trial failure rates. Nevertheless, advances in genetic research involving ALS-associated mutations such as SOD1, C9orf72, TARDBP, and FUS are supporting precision medicine development, while collaborations between biotechnology companies and academic institutions and expedited regulatory pathways are accelerating the development of promising therapies.
Key Features of the Study
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global amyotrophic lateral sclerosis (ALS) market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Biogen Inc., Mitsubishi Tanabe Pharma Corporation, Sanofi. Otsuka Pharmaceutical Co., Ltd., Eisai Co., Ltd., Ionis Pharmaceuticals, Inc., AB Science, BrainStorm Cell Therapeutics Inc., Clene Inc., and Sun Pharmaceutical Industries Limited
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global amyotrophic lateral sclerosis (ALS) market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global amyotrophic lateral sclerosis (ALS) market
Market Segmentation
- Drug Type Insights (Revenue, USD Mn, 2021 - 2033)
- Sodium Phenylbutyrate and Taurursodiol
- Edaravone
- Nuedexta
- Tofersen
- Riluzole
- Muscle Relaxants
- Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
- Others
- Route of Administration Insights (Revenue, USD Mn, 2021 - 2033)
- Oral
- Parenteral
- Others
- Dosage Form Insights (Revenue, USD Mn, 2021 - 2033)
- Oral Suspension
- Injectable
- Tablets
- Others
- Distribution Channel Insights (Revenue, USD Mn, 2021 - 2033)
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies
- Regional Insights (Revenue, USD Mn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Biogen Inc.
- Mitsubishi Tanabe Pharma Corporation
- Sanofi
- Otsuka Pharmaceutical Co., Ltd.
- Eisai Co., Ltd.
- Ionis Pharmaceuticals, Inc.
- AB Science
- BrainStorm Cell Therapeutics Inc.
- Clene Inc.
- Sun Pharmaceutical Industries Limited
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Amyotrophic Lateral Sclerosis (ALS) Market, By Drug Type
- Global Amyotrophic Lateral Sclerosis (ALS) Market, By Route of Administration
- Global Amyotrophic Lateral Sclerosis (ALS) Market, By Dosage Form
- Global Amyotrophic Lateral Sclerosis (ALS) Market, By Distribution Channel
- Global Amyotrophic Lateral Sclerosis (ALS) Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Market Opportunities
- Regulatory Scenario
- Industry Trends
4. Global Amyotrophic Lateral Sclerosis (ALS) Market, By Drug Type, 2021-2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Sodium Phenylbutyrate and Taurursodiol
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Edaravone
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Nuedexta
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Tofersen
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Riluzole
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Muscle Relaxants
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
5. Global Amyotrophic Lateral Sclerosis (ALS) Market, By Route of Administration, 2021-2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Parenteral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
6. Global Amyotrophic Lateral Sclerosis (ALS) Market, By Dosage Form, 2021-2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Oral Suspension
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Injectable
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Tablets
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
7. Global Amyotrophic Lateral Sclerosis (ALS) Market, By Distribution Channel, 2021-2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
8. Global Amyotrophic Lateral Sclerosis (ALS) Market, By Region, 2021 - 2033, Value (USD Mn)
- Introduction
- Market Share (%) Analysis, 2026, 2029 & 2033, Value (USD Mn)
- Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Mn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Drug Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Dosage Form, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Drug Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Dosage Form, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Drug Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Dosage Form, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Drug Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Dosage Form, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Drug Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Dosage Form, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Drug Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Dosage Form, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Mn)
- South Africa
- North Africa
- Central Africa
9. Competitive Landscape
- Company Profile
- Biogen Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Mitsubishi Tanabe Pharma Corporation
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sanofi
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Otsuka Pharmaceutical Co., Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Eisai Co., Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Ionis Pharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AB Science
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- BrainStorm Cell Therapeutics Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Clene Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sun Pharmaceutical Industries Limited
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Biogen Inc.
10. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
11. References and Research Methodology
- References
- Research Methodology
- About us
